Telix Pharmaceuticals (NASDAQ:TLX) Rating Lowered to Sell at Wall Street Zen

Telix Pharmaceuticals (NASDAQ:TLX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other research firms have also issued reports on TLX. HC Wainwright restated a “buy” rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a research note on Tuesday, January 27th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $21.00.

Telix Pharmaceuticals Stock Up 2.0%

Shares of NASDAQ TLX opened at $7.10 on Friday. Telix Pharmaceuticals has a 12-month low of $6.87 and a 12-month high of $30.36. The company has a 50-day moving average of $8.07 and a 200 day moving average of $9.77.

Institutional Investors Weigh In On Telix Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Rhumbline Advisers lifted its stake in Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after acquiring an additional 1,392 shares in the last quarter. IHT Wealth Management LLC purchased a new stake in Telix Pharmaceuticals during the second quarter worth about $213,000. Blair William & Co. IL acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth about $217,000. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Telix Pharmaceuticals in the second quarter valued at approximately $297,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Telix Pharmaceuticals in the third quarter valued at approximately $243,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.